|

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

RECRUITINGPhase 4Sponsored by Janssen Research & Development, LLC
Actively Recruiting
PhasePhase 4
SponsorJanssen Research & Development, LLC
Started2022-03-09
Est. completion2037-07-29
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations28 sites
View on ClinicalTrials.gov →

NCT05201781

Summary

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
* Participants who have provided informed consent for this study

Conditions2

CancerMultiple Myeloma

Locations28 sites

Mayo Clinic Cancer Center-Scottsdale
Phoenix, Arizona, 85054
City of Hope
Duarte, California, 91010
University of California San Francisco
San Francisco, California, 94143
Stanford University Medical Center
Stanford, California, 94305-5623
Moffitt Cancer Center
Tampa, Florida, 33612

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.